-

Metagenomi to Present at the Cold Spring Harbor Laboratory’s Genome Engineering: CRISPR Frontiers Conference

EMERYVILLE, Calif.--(BUSINESS WIRE)--Metagenomi, a gene editing company with a versatile portfolio of next-generation CRISPR tools, announced today that it will present a poster at the Cold Spring Harbor Laboratory’s Genome Engineering: CRISPR Frontiers conference, which will be held virtually August 18-20, 2021.

The poster describes Metagenomi’s newly discovered CRISPR-associated transposase (CAST) systems, which allow for targetable integration of large DNA fragments into genomes. These systems have the potential to overcome limitations of current approaches that could be used to replace defective, disease-causing genes. Metagenomi’s scientists extensively mined environmental metagenomics datasets to identify these systems and showed that they are active in E. coli. This work is based on Metagenomi’s proprietary high-throughput screening methodologies and leverages the newly discovered collection of CASTs in order to streamline these multi-component systems. These advancements will enable further development for in vivo and ex vivo gene editing applications.

Details of the poster are below:

Title: Engineered CRISPR-associated Transposases with Minimized Components
Presenting Author: Jason Liu, Ph.D.
Session Time: Poster will be available at 9:30 a.m. ET, August 18, 2021

About Metagenomi

Metagenomi is a gene editing company committed to developing potentially curative therapeutics by leveraging a proprietary toolbox of next-generation gene editing systems to accurately edit DNA where current technologies cannot. Our metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. We adapt and forge these naturally evolved systems into powerful therapeutic tools that can be leveraged by partners and fuel our own pipeline of novel medicines. Our goal is to revolutionize gene editing for the benefit of patients around the world. For more information, please visit https://metagenomi.co/.

Contacts

Media:
Ashlye Hodge
ashlye@metagenomi.com
+1 (510) 734-4409
Follow us on Twitter: @metagenomi

Industry:

Metagenomi

Release Versions
English

Contacts

Media:
Ashlye Hodge
ashlye@metagenomi.com
+1 (510) 734-4409
Follow us on Twitter: @metagenomi

More News From Metagenomi

Affini-T Therapeutics & Metagenomi Announce Next-Generation Gene Editing Partnership to Advance Cell Therapies for Solid Tumor Patients

BOSTON & SEATTLE & EMERYVILLE, Calif.--(BUSINESS WIRE)--Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, and Metagenomi, Inc., a genetic medicines company with a versatile portfolio of next-generation, wholly-owned gene editing tools, today announced a partnership to enable Affini-T’s next generation ex vivo T cell receptor (TCR) cell therapies for solid tumor patients using Metagenomi’s novel proprietary gene editing system...

Metagenomi Presents New Preclinical Data at ASGCT on Proprietary, Highly Efficient CRISPR Gene Editing Systems and a Novel Family of CRISPR-Associated Transposases (CASTs)

EMERYVILLE, Calif.--(BUSINESS WIRE)--Metagenomi, a genetic medicines company with a versatile portfolio of wholly-owned, next-generation gene editing tools, today presented new preclinical data on proprietary CRISPR-associated systems that have the potential to be used in the development of cell therapy and a novel family of CRISPR-associated transposases (CASTs) at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting. The first presentation demonstrates that Metagenomi’s g...

Metagenomi to Present New Preclinical Data at the Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

EMERYVILLE, Calif.--(BUSINESS WIRE)--Metagenomi today announced that two presentations will be made at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting....
Back to Newsroom